Weight Loss Injections

Mounjaro (Tirzepatide) injections

You may have seen information in the media recently about the release of NICE guidance (TA1026) Mounjaro (Tirzepatide) injections for managing Obesity and Overweight in Adults, as well as its use to treat Type 2 Diabetes. 

PLEASE NOTE:

We are currently waiting for an update from Cornwall & Isles of Scilly Integrated Care Board on whether we as a county will be delivering this service.

Mounjaro for Obesity:

Alert

From 23rd June 2025 GPs will be able to prescribe Mounjaro on the NHS to certain cohorts of patients that meet strict eligibility criteria. 

Cohorts for Mounjaro prescribing in General Practice

NHS England have defined the first 3 cohorts of patients who will be able to access Mounjaro via their GP on the NHS. 

The cohorts have been decided nationally by NHS England, this is to prioritise treatment by clinical need.

The initial first 3 years will see approximately 220,000 individually nationally become eligible for treatment on the NHS. 

At a PCN level, we estimate that the number of our patients eligible for Mounjaro for weight management will be less than 20. 

It is expected that after the first 3 years, the cohorts for eligiblity will expand again; however this is to be confirmed. 

The interim commissioning policy from NHS England can be viewed here: Interim commissioning guidance NICE TA1026 - Mounjaro for the management of obesity

Expand the buttons below to view the cohorts as defined by NHS England. 

Cohort 1: June 2025

A BMI of 40 or higher, or 37.5 or higher if from South Asian, Chinese, other Asian, Middle Eastern, Black African or African-Caribbean ethnic backgrounds.

At least 4 of the following comorbidities:

  • Hypertension and on treatment for blood pressure
  • Dyslipidaemia (high cholesterol) or on cholesterol treatment "statins"
  • Obstructive Sleep Apnoea 
  • Cardiovascular disease 
  • Type 2 diabetes
Cohort 2: June 2026 (TBC)

A BMI of 35 or higher, or 32.5 or higher if from South Asian, Chinese, other Asian, Middle Eastern, Black African or African-Caribbean ethnic backgrounds.

At least 4 of the following comorbidities:

  • Hypertension and on treatment for blood pressure
  • Dyslipidaemia (high cholesterol) or on cholesterol treatment "statins"
  • Obstructive Sleep Apnoea 
  • Cardiovascular disease 
  • Type 2 diabetes
Cohort 3: April 2027 (TBC)

A BMI of 40 or higher, or 37.5 or higher if from South Asian, Chinese, other Asian, Middle Eastern, Black African or African-Caribbean ethnic backgrounds.

At least 3 of the following comorbidities:

  • Hypertension and on treatment for blood pressure
  • Dyslipidaemia (high cholesterol) or on cholesterol treatment "statins"
  • Obstructive Sleep Apnoea 
  • Cardiovascular disease 
  • Type 2 diabetes
I think I might fit criteria 1 - what do I do?

Once we get confirmation from the ICB that we can provide this service and if you feel that you meet the criteria in Cohort 1, the first step is to contact the practice to provide an up to date height and weight, so that we can calculate your BMI. 

We will then check your other conditions (comorbidities) to confirm whether or not you meet the criteria. 

If your BMI and comorbidities suggest you may be suitable for Mounjaro, we will then contact you to book an appointment with your GP.

Please note that you will also be weighed by the practice at this appointment. 

You will also be required to engage in a weight management support programme which will be commissioned nationally by NHS England to support patients being prescribed Mounjaro. This is a condition of prescribing set by NHS England.